Nebraska Oncology Society
N

ASCO® 2024 Review: Metastatic Bladder Cancer Treated with EV + Pembro & Impact of PRO From EV-302

By Nebraska Oncology Society FEATURING Nataliya Mar
By Nebraska Oncology Society FEATURING Nataliya Mar
0 views
July 30, 2024
Comments 0
Login to view comments. Click here to Login

Recommended

AUTOPLAY
16:05
Insights from 2024 ASCO® GU Annual Meeting

Recent GU Developments and Their Clinical Implications

Feat. T. Powles, B. Rini
20:41
2024 ASCO® Annual Meeting Insights Hub

Bladder Cancer Highlights From ASCO® 2024

Feat. G. Sonpavde
29:25
Young Chae

Hyperprogression in Cancer Treated With Immunotherapy

15:58
Total Health

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

Feat. M. Reimers
22:19
Insights from 2023 ESMO Annual Meeting

Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting …

Feat. G. Sonpavde
17:32
Kriti Mittal

Current Updates in Urothelial Cancer: Clinical Implications for Prac…

22:27
2024 ASCO® Annual Meeting Insights Hub

Developmental Therapeutics Highlights From ASCO® 2024

Feat. G. Sonpavde
14:00
Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Summary: "Key Highlights in Bladder/Urothelial Ca…

Feat. G. Sonpavde
22:07
Weill Cornell Medicine Oncology & Hematology

Urothelial Carcinoma: New Developments

Feat. C. Sternberg
19:30
Scripps Health

Sequencing 1L Therapies in Metastatic Urothelial Carcinoma

Feat. P. Grivas
06:01
ecancer

ESMO 2023 Insights: "Phase 3 EV-302 Trial - Evaluating the Comb…

Feat. T. Powles
10:19
University of Colorado Cancer Center

NCCN Guidelines Updates for the Treatment of Metastatic Urothelial C…

Feat. T. Flaig
30:03
UCSF School of Medicine

Recent Advances in Advanced Urothelial Cancers: Time for a New Stand…

Feat. T. Friedlander
09:40
UCSF School of Medicine

Trastuzumab Deruxtecan Approval for Metastatic HER2+ Bladder Cancer

Feat. V. Koshkin
11:29
Oncology Data Advisor

Enfortumab Vedotin + Pembro for Previously Untreated Advanced Urothe…

Feat. T. Powles
15:28
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Bladder and RCC Highlights"

Feat. K. Tawagi, N. Reizine
13:54
AdventHealth

FDA Approval of Gemcitabine-Cisplatin + Nivo as 1L Therapy for Advan…

Feat. G. Sonpavde
17:03
Total Health

Emerging Trends in Localized Bladder Cancer in 2024

Feat. N. Gopal
04:16
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "KEYNOTE-361 Trial - Quantitative ctDNA As…

Feat. T. Powles
09:12
AdventHealth

Update on the FDA Accelerated Approval of Enfortumab Vedotin + Pembr…

Feat. G. Sonpavde